

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7217379

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SHU FENG	05/17/2021
SHU WEN SAMATHA HO	05/06/2021
RECEIVING PARTY DATA	
Name:	CHUGAI PHARMABODY RESEARCH PTE. LTD.
Street Address:	3, BIOPOLIS DRIVE, #07-11 TO 16
City:	SYNAPSE
State/Country:	SINGAPORE
Postal Code:	138623
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17670917
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617)542-5070
Email:	apsi@fr.com
Correspondent Name:	JANIS K. FRASER, PH.D., J.D.
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O. BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	14875-0277002
NAME OF SUBMITTER:	CATHY A. O'BRIEN
SIGNATURE:	/Cathy A. O'Brien/
DATE SIGNED:	03/10/2022
Total Attachments: 3	
source=Assignment_Chugai_Pharmabody_14875-0277002#page1.tif	
source=Assignment_Chugai_Pharmabody_14875-0277002#page2.tif	
source=Assignment_Chugai_Pharmabody_14875-0277002#page3.tif	

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, SHU FENG and SHU WEN SAMANTHA HO, each individually assign to CHUGAI PHARMABODY RESEARCH PTE LTD, a corporation formed under the laws of Singapore and having a principal place of business at 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 Singapore, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in a patent application that names us as inventors, is titled "DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF," and was filed in the United States Patent and Trademark Office on March 30, 2021, as application 17/216,981 (the "Application").

This Assignment assigns, in addition to the Subject Matter, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment

We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Fas Shu
Shu Feng

Date May 17th 2021


Witnessed by

Signature [Signature]
Print Name. SUN YANGLI

Date: 17/05/2021

Signature [Signature]
Print Name. NASA SAVORY

Date 17/05/2021


Shu Wen Samantha Ho


Date: 6 May 2021

Witnessed by:

Signature: 

Date: 6 May 2021

Print Name On Hsueh Ling Janice


Signature: 

Date 6 May 2021

Print Name: Su Yunpin

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee CHUGAI PHARMABODY RESEARCH PTE. LTD

Signature 

Date 31st May, 2021

Name: Hideaki Shimada

Title: Director, Chief Executive Officer and Research Head

24108850 doc